S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
NASDAQ:NBTX

Nanobiotix News Headlines

$8.98
0.00 (0.00%)
(As of 01/21/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.98
$8.98
50-Day Range
$7.13
$9.85
52-Week Range
$6.51
$20.00
Volume
39 shs
Average Volume
6,653 shs
Market Capitalization
$312.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Get Nanobiotix News Delivered to You Automatically

Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Nanobiotix Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NBTX
News Sentiment

0.00

0.40

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NBTX Articles
This Week

0

0

NBTX Articles
Average Week



Nanobiotix (NASDAQ:NBTX) News Headlines Today

SourceHeadline
finance.yahoo.com logoNANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets
finance.yahoo.com - January 10 at 7:05 AM
msn.com logoNanobiotix Rallies After Enrolling First Patient in Head and Neck Cancer Treatment
msn.com - January 6 at 11:39 PM
seekingalpha.com logoNanobiotix enrolls 1st patient in phase 3 trial of NBTXR3 in head, neck cancer
seekingalpha.com - January 5 at 8:04 PM
finance.yahoo.com logoNANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer
finance.yahoo.com - January 5 at 8:04 PM
finance.yahoo.com logoNanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022
finance.yahoo.com - January 4 at 6:40 PM
finance.yahoo.com logoNANOBIOTIX to Present at the 4th Annual Evercore ISI HealthCONx Conference
finance.yahoo.com - November 17 at 6:37 PM
finance.yahoo.com logoNANOBIOTIX Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkpoint Inhibitor Combination
finance.yahoo.com - November 9 at 6:54 PM
finance.yahoo.com logoNANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC in Phase I Expansion Evaluating Nbtxr3 as a Single Agent Activated by Radiotherapy
finance.yahoo.com - October 24 at 8:38 PM
finance.yahoo.com logoNANOBIOTIX Provides Third Quarter Operational and Financial Update
finance.yahoo.com - October 20 at 5:02 PM
finanznachrichten.de logoNanobiotix: Statement of Total Voting Rights and Shares Forming the Company's Share Capital
finanznachrichten.de - October 10 at 8:12 PM
finance.yahoo.com logoNanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
finance.yahoo.com - October 8 at 8:01 PM
finance.yahoo.com logoNanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
finance.yahoo.com - October 8 at 8:01 PM
finance.yahoo.com logoNANOBIOTIX to Present First Survival Data From Priority Head and Neck Cancer Program Among Five Presentations at the 2021 Annual Meeting of the American Society for Radiation Oncology
finance.yahoo.com - October 7 at 3:44 AM
finance.yahoo.com logoNANOBIOTIX Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May "Reprogram" the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect
finance.yahoo.com - September 28 at 10:20 PM
finance.yahoo.com logoNanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital as of August 31, 2021
finance.yahoo.com - September 9 at 8:44 PM
finanznachrichten.de logoNANOBIOTIX S.A.: NANOBIOTIX Provides Business Update and Reports Financial Results for the First Half of 2021
finanznachrichten.de - September 8 at 5:15 PM
finance.yahoo.com logoNANOBIOTIX Provides Business Update and Reports Financial Results for the First Half of 2021
finance.yahoo.com - September 8 at 5:15 PM
finance.yahoo.com logoNanobiotix to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
finance.yahoo.com - September 7 at 8:26 PM
finance.yahoo.com logoNanobiotix to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
finance.yahoo.com - September 7 at 8:26 PM
finance.yahoo.com logoNanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital as of July 31, 2021
finance.yahoo.com - August 6 at 1:35 PM
finance.yahoo.com logoNanobiotix Provides Second Quarter Operational and Financial Update
finance.yahoo.com - July 20 at 8:12 PM
finance.yahoo.com logoNanobiotix Starts New NBTXR3 Study In Lung Cancer Patients
finance.yahoo.com - July 1 at 1:55 PM
finance.yahoo.com logoNANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer
finance.yahoo.com - June 30 at 7:17 PM
finance.yahoo.com logoDo Hedge Funds Love Nanobiotix S.A. (NBTX)?
finance.yahoo.com - June 23 at 6:49 PM
finance.yahoo.com logoNanobiotix's Nanoparticle Technology Shows Tumor-Killing Effect in Early-Stage Head & Neck Cancer
finance.yahoo.com - June 4 at 1:24 PM
benzinga.com logoNANOBIOTIX Reports New Data for Potential First-...
benzinga.com - June 3 at 10:06 PM
markets.businessinsider.com logoNANOBIOTIX to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
markets.businessinsider.com - May 26 at 11:17 PM
businesswire.com logoNanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting ...
businesswire.com - May 20 at 8:50 AM
finance.yahoo.com logoNanobiotix, LianBio Ink NBTXR3 Development Pact In Asia For Solid Tumor Settings
finance.yahoo.com - May 12 at 11:19 AM
markets.businessinsider.com logoNANOBIOTIX Announces First Quarter Operational and Financial Updates
markets.businessinsider.com - April 29 at 7:27 PM
businesswire.com logoNANOBIOTIX Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F
businesswire.com - April 7 at 6:57 PM
markets.businessinsider.com logoNANOBIOTIX Reports Full Year 2020 Financial Results and Highlights Operational Progress
markets.businessinsider.com - March 17 at 5:44 PM
finance.yahoo.com logoNanobiotix, PharmaEngine Terminate Development Pact For Radiation Therapy In APAC Region
finance.yahoo.com - March 5 at 11:49 AM
businesswire.com logoNANOBIOTIX and PharmaEngine Mutually Agree to Conclude Collaboration
businesswire.com - March 4 at 7:15 PM
finance.yahoo.com logoNANOBIOTIX to Present at the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 3 at 8:01 PM
businesswire.com logoNANOBIOTIX 2020 Q4 and Annual Revenues
businesswire.com - February 26 at 6:56 PM
markets.businessinsider.com logoNANOBIOTIX Announces First Patient Injected With NBTXR3 in Esophageal Cancer
markets.businessinsider.com - January 28 at 5:21 PM
finance.yahoo.com logoNanobiotix Subsidiary Curadigm Secures New Collaboration Agreement With Sanofi Focused on Gene Therapy Pipeline
finance.yahoo.com - January 25 at 7:50 PM
businesswire.com logoNANOBIOTIX Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021
businesswire.com - January 15 at 3:41 AM
barrons.com logoNanobiotix S.A. ADR
barrons.com - January 10 at 10:40 PM
markets.businessinsider.com logoNanobiotix Announces Closing of Underwriters’ Option to Purchase Additional ADSs
markets.businessinsider.com - December 20 at 2:22 AM
benzinga.com logoNanobiotix Announces Closing of Underwriters' Option to Purchase Additional ADSs
benzinga.com - December 18 at 6:17 PM
nasdaq.com logoNanobiotix SA Rings the Closing Bell
nasdaq.com - December 18 at 12:44 AM
Get Nanobiotix News Delivered to You Automatically

Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.